Search Results

Displaying Results 1-2 of 2 "'HGBL'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight

Aug 27, 2025, 17:31 ET Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight

refractory large B-cell lymphoma (LBCL), including DLBCL not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.Diffuse

More news about: DelveInsight Business Research, LLP

Jun 12, 2025, 05:17 ET Sobi share new clinical data across multiple hematologic diseases at EHA 2025

is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. About Sobi®  Sobi is a global biopharma company unlocking the potential of breakthrough

More news about: Swedish Orphan Biovitrum AB

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.